Phaseline

Companies › Prove pharm

Prove pharm: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 4; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Indigotindisulfonate sodium 0.8%
Visualization dye for determining ureteral patency
–Phase 4Ureter InjuryDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06054880Indigotindisulfonate sodium 0.8%Phase 4Ureter InjuryOtherMar 2026
NCT06085183Indigotindisulfonate sodium 0.8%Phase 4Ureter InjuryOtherDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Neuraptive Therapeutics Primus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.